A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 309
- Registration Number
- NCT01783444
- Locations
- 🇺🇸
University of California at Los Angeles Mattel Children's Hospital, Los Angeles, California, United States
🇺🇸Sharp Memorial Hospital SharpClinicalOncologyResearch, San Diego, California, United States
🇺🇸Oncology Hematology Care Inc Oncology Hematology Care 2, Cincinnati, Ohio, United States
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 215
- Registration Number
- NCT01784068
- Locations
- 🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Lakes Research, Miami Lakes, Florida, United States
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3362
- Registration Number
- NCT01782326
- Locations
- 🇬🇧
Novartis Investigative Site, Wiltshire, United Kingdom
Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 671
- Registration Number
- NCT01780935
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
Indacaterol EfectIveness In COPD Patients With Tuberculosis History
- Conditions
- Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
- Interventions
- Drug: Control
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 136
- Registration Number
- NCT01778062
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 332
- Registration Number
- NCT01775124
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2015-11-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT01775137
- Locations
- 🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung CancerAnaplastic Lymphoma Kinase (ALK)
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT01772797
- Locations
- 🇺🇸
Massachusetts General Hospital Mass General, Boston, Massachusetts, United States
🇺🇸Fox Chase Cancer Center Fox Chase Cancer (2), Philadelphia, Pennsylvania, United States
🇪🇸Novartis Investigative Site, Barcelona, Catalunya, Spain
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients
- First Posted Date
- 2013-01-17
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 114
- Registration Number
- NCT01769768
- Locations
- 🇺🇸
Massachusetts General Hospital Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock Med Ctr, Lebanon, New Hampshire, United States
Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Secukinumab (AIN457)Biological: Placebo
- First Posted Date
- 2013-01-17
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 242
- Registration Number
- NCT01770379
- Locations
- 🇿🇦
Novartis Investigative Site, Panorama, Western Cape, South Africa